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Abstract
Background: This systematic scoping review aimed to identify changes in biomarkers of microbiological,
immunological and biochemical origin during experimental gingivitis (EG) studies that might indicate resistance
and resilience.
Methods: The term ‘experimental gingivitis’ was run in PubMed from inception to April 11th, 2018. From the 411
studies retrieved, 22 studies were included for this review.
Results: Studies reporting data on biomarker changes during and after full mouth EG trial were included. Two studies
reported findings on changes in biomarkers of microbiological, 12 on immunological and eight on biochemical origin.
Changes were reported in the induction phase, and occasionally in the resolution phase. The microbiological
composition of both supragingival and subgingival dental plaque changed over the course of EG to a more
pathogenic direction, but showed a shift back to a more normal composition. This indicates resilience of the oral
microbiome. For immunological biomarkers, it was challenging to retrieve a robust pattern of changes across
multiple studies. IL-1β and IL-6 in saliva and in gingival crevicular fluid increased during induction phase and
returned in the resolution phase below baseline values. The biochemical parameters cystatin-SN, cystatin-S and
lactoferrin in saliva were increased at the end of induction phase, however also here no clear pattern emerged
based on all available studies.
Conclusions: More research is needed to investigate which microbiological, immunological, and biochemical
biomarkers can be useful for future investigations into the resistance and resilience of the oral cavity to experimental
gingivitis.
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Background
Plaque accumulation and gingival responses to the ab-
sence of oral hygiene vary from person to person [1].
However, when oral hygiene practices are restored, values
of plaque index and gingival index drop rapidly, indicating
a reversible inflammation mechanism of the gingiva. The
most frequently used longitudinal design for modelling
the early phases of gingival inflammation is the experi-
mental gingivitis (EG) protocol, originally developed by
Löe et al. to demonstrate that de novo accumulation of
plaque was associated with the development of gingivitis
[1]. Participants were asked to refrain from any form of
oral hygiene to induce plaque accumulation until gingival
inflammation occurred. The time frame for development
of gingivitis varied from 10 to 21 days. Different protocols
have been developed thereafter with the addition of an
intervention or a pre-trial phase. This phase typically con-
sists of professional prophylaxis to achieve zero inflamed
gingival tissues so that effects of plaque accumulation
alone could be studied. Eventually the induction phase
ended with professional prophylaxis to restore gingival
health. By demonstrating that removal of plaque resolved
gingival inflammation, strong evidence was provided that
plaque causes gingivitis [1]. A recent study showed little
to no inflammation and no red fluorescent plaque in some
participants during an EG trial, while other participants
have shown high levels of plaque and gingival
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inflammation [2]. In this study, such subjects are referred
to as high or low responders, respectively, to the exposure.
Subjects can have a high resistance to perturbation or EG,
in which few changes occur in the oral ecosystem, there-
fore will have little restoration after the trial. A low resist-
ance means that the impact on the ecosystem is high
(Fig. 1). Resilience is defined as the property of the oral
ecosystem to recover to its initial state [3]. In the EG trial,
participants can have a high (full) or low (incomplete) re-
silience after the experiment (Fig. 1). Factors associated
with resilience of the periodontal/gingival tissue to pertur-
bating factors could include genetics and/or lifestyle fac-
tors such as smoking, diet and psychosocial factors [4]. In
the case of EG, the pre-existing inflammatory status and
the condition of the oral cavity as a whole in the pre-trial
phase could influence the outcome of the study, and thus
determine resilience [5].
The EG trial has been adapted by many research
groups resulting in a variety of protocols being adopted
for each phase. The experiment is used to study a large
diversity of outcomes from clinical, microbiological to
immunologic outcomes, and subjects, from healthy sub-
jects to the comparison of systemically unhealthy study
participants or pregnant women. In this systematic scop-
ing review we aimed to identify in EG studies changes in
biomarkers of microbiological, immunological and bio-
chemical origin that might indicate resistance and resili-
ence. We searched for potential markers of resistance
and resilience in the induction and resolution phase re-
spectively. The retrieved evidence is tabulated and
knowledge indications for resistance and resilience, or
gaps in the literature, are presented for future research.
Methods
Study design
The preliminary assessment of the size and scope of
available research literature regarding oral resilience to
EG was conducted according to the JBI Briggs Reviewers
Manual and the PRISMA statement for transparent
reporting of systematic reviews and meta-analysis [6, 7]
In order to ensure systematic reviewing of the literature,
the PRISMA checklist and guideline was used through-
out the review process.
Electronic search
The search string was specified and limited to the use of
the words ‘experimental gingivitis’ in parenthesis and
run in PubMed from inception to April 11th, 2018. This
specified search string would limit references to those
focusing only on EG, leading to a large reduction in ir-
relevant references when compared with other search
string options. The hits arising from the search strategy
were exported to RAYYAN, a systematic review web ap-
plication [8], for the screening process.
Screening process
The search hits were screened independently by C.Z. and
N.J. based on title, abstract, and full text and conflicting
results were discussed to reach consensus. Data extraction
was double checked by B.G.L. The selected studies for full
text screening were exported to EndNote. Full text studies
were retrieved using EndNote, Google, Research Gate or
by contacting the corresponding author. References con-
taining data on immunological, microbiological, and bio-
chemical parameters were included. These data were
required to provide an indication or indirect evidence on
resistance and/or resilience of the oral cavity during and
after the EG trial. Studies on mouth rinses, placebo con-
trol groups, animals, surgical treatments, antibiotics,
Fig. 1 Definitions of resistance and resilience in the current systematic
scoping review on EG. In Panel a we define resistance, i.e. the ability to
remain unchanged during perturbation (arrows in a and b): High
resistance is defined as a low response during induction phase (a),
while low resistance is defined as a high response during the induction
phase (b). In Panel b we define resilience, i.e. the ability to recover to
the initial sate after perturbation: High resilience is defined as fast and
full recovery during resolution phase (c), while low resilience is defined
as slow or incomplete recovery during the resolution phase (d).
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probiotics, those lacking a healthy control population,
cross-sectional designs, any form of intervention during
the induction phase, and split mouth experimental design
were excluded. The latter type studies were excluded due
to risk of transfer of fluids and biomarkers from one part
of the oral cavity to another. Moreover, systemic re-
sponses are likely to be lower in a split mouth study de-
sign than in full-mouth EG due to the smaller gingival
surface area of inflammation; this may then affect the in-
flammatory profile of plasma and GCF.
Data management
Data on study setup, parameters and study characteristics
were reported in separate tables. The data were summa-
rized narratively to provide an overview of retrieved evi-
dence and reported resilience based on microbiological,
immunological and biochemical origin. For each study we
conducted a risk of bias assessment using the JBI checklist
for analytical cross sectional studies. We have categorized
the risk of bias scores as follows: < 4, high risk of bias; 4–
5, moderate risk of bias; 6–7, low risk of bias.
Results
The search strategy yielded 411 publications, of which
104 were screened based on full text analysis. Finally, 22
unique studies were included for the current review
(Fig. 2). The details of the included studies are reported
in Table 1. A list of excluded studies based on full text is
provided in Additional file 1. It was noted that 18 of
these studies were excluded on the basis that full text
was not available. These were generally in smaller sub-
scription-only dental journals and we were unable to ac-
cess the documents. In total, two studies reported
microbiological findings [22, 23], eight studies studied
biochemical changes [10, 12–14, 21, 24–27] and 12 ana-
lyzed immunological results [9, 11, 15–20, 28–30]. Full
descriptions of all studied parameters are mapped in
Additional file 2. The protocols in the included studies
differed in terms of time lines, coverage of phases and
comparison groups. No studies specifically set out to
identify factors associated with resilience of the oral cav-
ity to the challenge arising from abstinence of oral hy-
giene measures. Five studies compared smokers to non-
smokers in exposure to the EG trial [18, 23–25, 29];
smoking status was always based on self-report and not
biochemically assessed. A sample size of less than 20 in-
dividuals was reported in 15 studies, while the six other
studies included from 21 to 156 subjects. Students were
used as a study population in 12 studies, of which nine
focused on dental students. Two studies examined
Fig. 2 PRISMA Flowchart of the search and selection process
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elderly versus younger adults and one study included
only children: Down syndrome and healthy. Apart from
the child study (ages not reported), the youngest and
oldest ages reported were 18 and 77. A total of 14 stud-
ies included a pre-trial phase, and nine studies added a
resolution phase to the experiment. The study setup, per
phase of the EG trial, is provided in Additional file 3.
Risk of bias assessment
Ten studies had a moderate risk of bias (scores 4–5) and
11 studies had a low risk of bias (scores 6–7). None of the
studies had taken confounding factors into account in the
final analysis, therefore no score ‘7’ was reached. The
complete risk of bias table is provided in Additional file 4.
Microbiological markers
Two studies investigated microbiological changes during the
EG trial and compared the outcomes in smokers and non-
smokers [22, 23]. Both studies were almost equal in size,
and both had professional prophylaxis in the pre-trial phase.
The study of Salvi et al. [23] using DNA-DNA
checkerboard hybridization techniques on subgingival
plaque samples, showed no differences in total DNA
probe counts during the induction phase (day 0 com-
pared with day 21) and after resolution (day 35 com-
pared with day 21). Species were grouped on the basis of
the colour-coded complexes identified by Socransky et
al. [31] in a checkerboard hybridization study of bacteria
associated with periodontal disease. Purple complex spe-
cies (Veillonella parvula and Actinomyces odontolyticus)
were significantly decreased in non-smokers at day 21
compared with baseline. Actinomyces sp. (blue complex)
and the yellow complex, containing oral streptococci
Streptococcus sanguinis, S. oralis, S. mitis, S. gordonii and
S. intermedius, increased in non-smokers during reso-
lution. By contrast, red complex species (Porphyromonas
gingivalis, Treponema denticola, and Tannerella. for-
sythia) that are most strongly associated with periodon-
titis were significantly elevated in smokers in subgingival
plaque by 21 days of EG, and significantly reduced over
the resolution phase, from day 21 to day 35, in both
smokers and non-smokers [23].
The study of Lie et al. [22] employed traditional
microbiological culture and identification to investigate
nine different microbial taxa in three different types of
dental plaque: supragingival, subgingival or approximal,
including swabs of the tongue and tonsils. In supragingi-
val dental plaque samples, the total CFU increased sig-
nificantly from baseline to the end of the EG phase (day
14) in non-smokers from 1.1 × 106 CFU to 3.7 × 106
CFU. By contrast, there was not a significant difference
over this phase in smokers. Aggregatibacter (formerly
Actinobacillus) actinomycetemcomitans, Parvimonas
micra (formerly Peptostreptococcus micros) and
Streptococcus spp. did not differ between groups or over
time in the induction phase. Similarly, there was no sig-
nificant difference over time in levels of A. actinomyce-
temcomitans, Campylobacter rectus, Fusobacterium
nucleatum, Streptococcus spp., and P. micra in subgingi-
val plaque, and total CFU, A. actinomycetemcomitans,
Streptococcus spp., and P. micros in approximal plaque
[22]. The mean total CFU of Campylobacter rectus and
F. nucleatum increased during EG in smokers and these
species, together with Actinomyces spp. and P. inter-
media, increased in non-smokers. Differences varied
from a 3.4-fold increase in Actinomyces spp. in non-
smokers between day 0 and 14 to a 29-fold increase in
P. intermedia in non-smokers over the same timeframe.
There was a significant increase in total CFU in subgin-
gival dental plaque in smokers, but not in non-smokers,
during EG, from 6.3 × 105 CFU to 3.4 × 106 CFU. Actino-
myces spp. and P. intermedia were increased in both
smokers and non-smokers. In approximal dental plaque,
Actinomyces spp. and C. rectus were increased by the
end of EG in non-smokers, F. nucleatum was increased
in smokers and P. intermedia was increased in both
smokers and non-smokers. There were no significant
changes in microbial counts between the start and end
of EG in samples from the tongue or tonsils [22].
Overall, these two studies [22, 23] demonstrate that
the microbiological composition of both supragingival
and subgingival dental plaque changes over the course
of EG and during resolution, and the changes appear to
be affected by smoking status. However, the study of
Salvi et al. [23] did not analyse changes in individual
species, and it is therefore impossible to identify consist-
ent markers of responsiveness or resilience on the basis
of these two studies alone.
Immunological markers
Biopsies and systemic findings
Three studies investigated leukocyte changes in the EG
trial [14, 20, 28]. They had a 21-day induction phase and
the levels of leukocytes, both in gingival biopsies and
peripheral blood, did not change in the induction phase
compared to baseline levels. Only in one study (N = 8)
polymorphonuclear neutrophils (PMNs) in gingival bi-
opsies were found to increase significantly from 18.1% at
the end of the EG trial (i.e. day 0 of resolution phase) to
21.9% at day 8 of the resolution phase [14]. This obser-
vation is counter intuitive, however the difference be-
tween 18.1 and 21.9% may not be clinically significant;
fibroblasts, lymphocytes, plasma cells and macrophages
did not show significant changes in the resolution phase.
As a result from inflammatory reactions, sICAM is
known to increase in plasma. In one study, sICAM-1 in
plasma, increased significantly 2.6-fold in the induction
phase and remained elevated during the 2 weeks of
Zemouri et al. BMC Oral Health          (2019) 19:212 Page 12 of 18
resolution phase [14]. The results for sICAM-1 in EG
and its resolution indicate a low resistance and low re-
silience to the occurring gingival inflammation. Here we
found another example where a biomarker remained
longer present in plasma while the gingiva has returned
to its healthy state. Interestingly, for the cytokine inter-
feron-γ there were no significant changes during the in-
duction and resolution phases [14], suggesting no major
involvement of this immune mediator in EG.
One study looked for immunoglobulins in serum. The
values of IgG, IgM and IgA of the EG subjects compared
to subjects who maintained normal oral hygiene,
remained stable during the induction period [19]. No
resolution phase was included.
Saliva
In the study of Zhou et al. [13], expression of interleukin
(IL)-1β in unstimulated whole saliva was significantly
higher during the induction phase and returned to base-
line levels at resolution suggesting that gingival health
improved at the end of the resolution phase to a (more)
healthy state and shows normal resilience and inflamma-
tory response to the challenge. In one small study of
Belstrøm et al. [30], IL-β levels in stimulated saliva were
decreased after 10 days of induction phase compared to
baseline levels. Mean IL-6 in whole saliva increased sig-
nificantly from 6.70 pg/mL at baseline to 7.86 pg/mL at
day 21 (end of induction). The values decreased to 7.05
pg/mL in the resolution phase, which was not signifi-
cantly different compared to day 0. Further, IL-8 levels
in stimulated saliva were reduced after 4 days of induc-
tion and remained low up to resolution phase [30]. Not-
ably, IL-2, IL-4, IL-5 and IL-10 in saliva did not
significantly change over time [12].
Immunoglobulins (Ig) were examined in three studies
[11, 18, 19]. IgA [19] secretion in stimulated parotid sal-
iva increased significantly from 20 μg/mL to 40 μg/mL in
the induction phase in a healthy study group. However,
the IgA secretion and concentration in resting parotid
saliva, submandibular/sublingual saliva (both resting and
stimulated) remained stable in this stage [18]. No data
were reported on the resolution phase [11].
Gingival crevicular fluid
Various IL were studied in six studies [13, 15–17, 19, 28,
29]. In two of these studies [13, 19], no changes in IL-4,
IL-5, IL-6, IL-8, IL-10 and IL-12 in gingival crevicular
fluid (GCF) were found during the induction phase. In
the study of Heasman et al. [15], IL-1β in GCF from 20
pooled sites/subject showed almost 8-fold increase from
16.5 ng/mL at baseline to 131 ng/ml at week 1, and
thereafter remained approximately at that level until the
end the experiment (28 days). A similar pattern was re-
ported by Leishman et al. [17]; interestingly they
included a resolution phase in their study and found that
IL-1β in GCF showed a decrease, beyond the levels of
baseline (52.91 pg/mL) to 9.64 pg/mL at the end of reso-
lution phase. In smokers participating in an EG trial, the
level of IL-1β in GCF, increased from baseline to day 10
of the induction phase, from 6.2 pg/20s to 13.6 pg/20s,
while in non-smokers the respective values were 3.99 pg/
20s to 9.8 pg/20s [19].
Another interleukin, IL-2 in GCF, increased from 7.81
pg/mL at baseline to 11.82 pg/mL at the end of the induc-
tion [13]. However, IL-2 levels dropped to below baseline
measurements of 0.59 pg/mL [13], suggesting a return to
normal non-inflamed gingiva and that gingival tissues at
baseline were somewhat inflamed to begin with.
The output rate of IL-4 was found in GCF to decrease
after 10 days of induction phase in non-smokers from
10.2 pg/20s to 5.5 pg/20s, and remained stable in smokers:
4.4 pg/20s to 4.1 pg/20s [19]. The response of IL-4 is in-
consistent with the data of Leishman et al. [17]. In this
study, the induction phase consisted of 21 days in which
the level of IL-4 in GCF did not significantly change over
time. However, it did drop to 0 after 14 days of resolution
indicating resilience to the trial by marker IL-4.
For IL-8 the output rate in GCF increased significantly
during the induction phase in smokers and non-smokers
(21.1 pg/20s to 56.1 pg/20s; 15.1 pg/20s to 36.5 pg/20s re-
spectively), with a significant higher increase in smokers
[29]. This might indicate that smokers have a higher host
response than non-smokers to an inflammatory challenge.
The study conducted by Tsalikis et al. [28] compared
TNF-α levels in GCF in old and young participants (61–
65 and 20–22 years). The values at baseline did not differ
between age groups. At day 21 of the induction phase, and
at day 7 of the resolution phase, the values were signifi-
cantly higher in the elderly participants, while the younger
participants did not show any changes over the total ex-
periment. This suggests that older age is associated with a
lower resistance to EG challenge than younger age. The
latter results are somewhat different from another study:
in the study conducted by Leishman et al. [17] with a
study population of a mean age of 25 years, the TNF-α
values in GCF increased during induction of a 3 week
period (0.98 pg/mL to 1.75 pg/mL) and decreased to 0.11
pg/mL in the resolution phase, i.e. indicating a high resili-
ence. However the contradictory results for TNF-α in
GCF between the two studies [17, 28], make it difficult to
draw a conclusion on the overall response to EG.
Only one study investigated the lipid immune media-
tors, PGE-2 and TxB2 in GCF samples. The result
showed that these mediators were not elevated during
the first 3 weeks. However, the values increased signifi-
cantly at the 4th week of the induction phase, suggesting
that resistance to EG may be weakened when the EG
was extended beyond the traditional 3 week period [15].
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Biochemical markers
Saliva
A full proteome analysis of whole saliva was conducted in
healthy adults [27]. Several proteins, listed in Table 1,
were found to show at least a two-fold increase in concen-
tration during the induction phase. Of these, 10 proteins
were identified having roles in protection of cells and tis-
sues: vitamin D-binding protein, thioredoxin, lactoferrin
(a.k.a. lactotransferrin), a G protein coupled receptor,
cystatin-SN, cystatin-S, collagen alpha 1(XXVII) chain,
beta-globin, annexin A1, and ALB protein. No data were
reported on proteome change in the resolution phase.
Salivary cystatin activity, output and total protein were
investigated in one EG study consisting of smokers and
non-smokers [24]. The mean protein concentration in
both groups did not significantly change over time. In
non-smokers, cystatin activity, output cystatin activity,
cystatin C and output cystatin C remained stable during
the induction phase. However, in smokers, a significant
decrease of cystatin activity from 36.2 to 28.8 (units/mL)
and decrease of output cystatin C (0.37 to 0.22 μg/min)
was observed at day 14 compared to baseline. When
changes at day 14 were compared between groups, non-
smokers showed to have a higher level of cystatin activ-
ity (49 vs 28.8 units/ml), cystatin C (0.63 vs 0.44 μg/ml),
output cystatin activity (31.6 vs 17.5 units/min), and out-
put cystatin C (0.46 vs 0.22 μg/min). We noted from this
one study on salivary cystatin parameters a tendency for
these biomarkers in non-smokers to remain stable dur-
ing the induction phase of EG, indicating that perhaps
these salivary factors do not play a major role in resist-
ance to EG. On the other hand, these parameters go
down in smokers, which may indicate that smokers have
less salivary protection capacity in an EG trial.
From the EG trial by Uitto et al. [12], concentrations of
salivary elastase levels in oral rinse samples were measured
at day 10 and day 15 of the induction phase, and no signifi-
cant differences were reported over time. In another study,
elastase activity in saliva samples increased significantly at
day 2 of the induction phase and remained elevated until
day 14, while it decreased again in the resolution phase to
baseline levels [13]. These results indicate that elastase ac-
tivity is a useful biomarker for resistance and resilience of
EG in periodontally healthy individuals.
Gingival crevicular fluid
An EG study conducted in 12 healthy male dental stu-
dents, measured levels of lactoferrin in GCF and found
significant increase from day 0 to the end of induction
phase (14 days) of 58.8 and 163.2 ng/μl, respectively [26].
This was consistent with the results found by Adonogia-
naki et al. [25], who also conducted their study with
GCF from healthy dental students (N = 6). In the reso-
lution phase, the lactoferrin levels returned to baseline
values. Lactoferrin in GCF might be a good biomarker
to indicate resistance (increase of antibacterial activity)
and resilience in EG.
In one EG study (N = 10), transferrin levels showed no
significant changes in blood and GCF during induction
phase [18]. This is inconsistent with the study of Adono-
gianaki et al. [25], in which transferrin levels seemed to
increase significantly over time, but did not return back
to baseline levels after resolution.
Calprotectin is an acute phase reactant to an inflamma-
tion associated with tissue destruction and neutrophil ac-
tion. Changes in calprotectin values reflect the degree of
gingival inflammation. The values showed to increase in
value over three-week EG period to 5 μg/ml indication an
inflammation [13]. After 1 week of resolution phase, the
inflammatory biomarker decreased to 1.7 μg/ml which
was lower than baseline value of 2.4 μg/ml. The latter indi-
cates that the oral cavity has a natural response to inflam-
mation and restores to improved state than baseline.
These findings were similar in a study in which the calpro-
tectin levels were measured in GCF during induction
phase [21]. However, the latter study included professional
prophylaxis at the end of the induction, where the levels
increased significantly 1 day after the intervention. This
protein might not be a marker for the level of gingival in-
flammation during EG-trial, to indicate either resilience or
resistance.
Biopsies and systemic findings
Lactoferrin in blood samples increased significantly from
112 ng/μl at day 0 to 200 ng/μl after 2 weeks of induction
phase and reduced to baseline values in the resolution
phase [26]. Similar to lactoferrin in GCF, sample values
from blood might also be a good sample location to
identify resilience to EG.
Norman et al. [19] studied the changes of CH50, and
complement component C4 in serum for 21 day induction
phase, and no resolution. The quantity increased signifi-
cantly at the end of induction compared to baseline. The
complement component molecule C3, Factor 8, alpha-
antitrypsin, microsomal prostaglandin-E synthase-1, and
cyclooxygenase-2, did not change in value during the in-
duction phase [16, 21, 24].
One study reported monocyte chemoattractant protein-
1 (MCP-1) and vascular endothelial growth factor (VEGF)
in dental students undergoing the EG-trial [30]. There
was a reduction of both markers during induction phase.
The latter study did not include a resolution phase. No
clear statements can be made on the markers as indicators
of resistance or resilience during EG trial.
Discussion
This systematic scoping review aimed to identify bio-
logical changes in the oral cavity during EG studies that
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might indicate resistance and resilience. EG was chosen
because it is a well-established longitudinal model that
has been used by many researchers. The search resulted
in studies with a large variety of modifications to the ori-
ginal EG study [1]. In order to reduce the level of het-
erogeneity, studies with split mouth experiments were
excluded as outlined in the Methods section (risk of
transfer of fluids/biomarkers, systemic responses). Des-
pite this, the results of the full mouth experiments were
difficult to compare with each other. The set-up of the
EG-phases and duration differed between studies. None
of the studies aimed to study resistance and/or resilience
to EG. Nevertheless the included studies gave some in-
sights in changes during the EG challenge. The magni-
tude of changes might indicate either high or low
resistance and/or resilience to the challenge. Only a
small number of studies investigated ‘recovery’ in the
resolution phase, therefore succeeded to identify markers
which could be translated to resilience. The findings re-
ported in this review regarding resistance and resilience
are obviously dependent on the trial duration. For ex-
ample, the study of Heasman et al. [15] showed that ex-
tending the EG trial to 4 weeks yields different results
than trials of 2 weeks. This might explain why in studies
with short induction and resolution phases, no clear re-
sults were found.
Only two of the included studies investigated the micro-
biological changes in an EG-trial [22, 23]. Using microbio-
logical culture, the most consistent change during EG was
an increase in P. intermedia, which occurred in 5/6 plaque
samples tested (supragingival plaque from non-smokers,
and subgingival and approximal plaque from smokers and
non-smokers) [24]. P. intermedia is a member of Socrans-
ky’s orange complex [31]. When this group was consid-
ered, it was not found to change during induction or the
resolution phase [23]. Actinomyces spp. increased consist-
ently during the induction of gingivitis in non-smokers,
and in the subgingival dental plaque of smokers [22]. Acti-
nomyces spp. may provide a useful indicator of resistance,
dependent on the sampling site and smoking status. How-
ever, this suggestion needs to be interpreted with care
since it was found only in one study with a limited num-
ber of smokers (n = 11) and non-smokers (n = 14). More-
over, we acknowledge that when reviewing/reporting on
studies involving smokers biochemical determination of
smoking status would be ideal rather than the commonly
applied self-reporting method. With regard to assessing
resilience on the basis of commensal beneficial oral bac-
terial species, there is a lack of evidence from full mouth
EG studies examining changes in the microbiome. More
detailed studies are urgently needed using modern next
generation sequencing approaches to study changes in the
full microbiome of gingival sites and other sites in the oral
cavity and saliva. So far, this has only been done in a study
of split mouth design and focused on the induction phase
alone [32].
Several immunological markers have been studied dur-
ing the course of EG and the subsequent resolution phase.
In short, it was virtually impossible to retrieve a robust
pattern of changes for one or several of these markers
across multiple studies: the markers were rarely measured
in the same EG design, validated in sufficient number of
studies, in a variety of media (biopsy, GCF, stimulated
whole saliva, unstimulated whole saliva, parotid saliva,
submandibular saliva) and the reported units of interest
varied for the same marker making overall conclusions
difficult. One study [13] showed some increase in the
number PMNs in gingival biopsies in the induction phase
of EG, but the increase was not clinically relevant.
Four studies [12, 13, 15, 28] support that IL-1β ap-
pears as a normal inflammatory reaction to the chal-
lenge, with significantly higher values in smokers. The
same parameter is a marker for resilience since the
values drop to below baseline levels. The same applies to
IL-6 [12]. Also, IgA levels may increase in the resolution
phase, but this was dependent on the analysis of either
stimulated or unstimulated saliva. It is not clear how
closely the amount of plaque (microbial load) is linked
to IgA secretion. In summary, we can conclude that the
usual pro-inflammatory markers may increase during
the induction phase of EG as a resistance marker, but
this is not consistently reported and gives no clues on
true mechanistic pathways related to susceptibility to the
levels of EG that develops in any given individual, let
alone that we have seen patterns that could indicate a
certain level of resilience to EG.
A number of biochemical markers in saliva have been
studied at the level of protein concentration or enzyme
activity during the course of EG. Proteomic analysis has
highlighted factors associated with cell and tissue protec-
tion as targets of regulation during EG [27]. The samples
for this study were stimulated whole saliva. Concentra-
tions of the protease inhibitors cystatin-SN and cystatin-
S were increased > 2-fold at day 21 compared to base-
line. Cystatins have antibacterial activity against certain
perio-pathogens [33, 34]. Therefore, increased cystatin
activity is an indicator of resistance to perturbation. Sev-
eral studies have shown that total cystatin activity is ele-
vated in saliva of periodontitis patients compared with
controls [33, 35, 36]. However, the picture is not entirely
clear as other studies have shown reduced total cystatin
activity and specific reductions in cystatin-SN and cysta-
tin-S in periodontitis patients [37, 38]. Although our
study excluded split mouth designs, it is important to
note that cystatins-B and -S were essentially unchanged
in GCF during 21 days of EG in one split mouth design
study [39]. The expression of cystatins may depend to
some extent on smoking status. Cystatin C levels were
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relatively constant during EG in non-smokers, but re-
duced significantly over this time in smokers [24]. Based
on this finding, smoking is a factor leading to low resist-
ance of the oral cavity, perhaps also reduce resilience.
Clearly, more work is required to determine whether
cystatin expression can be a useful indicator of resili-
ence, and again, a biochemical confirmation for smok-
ing/non-smoking would be best.
Metal ion sequestration is thought to be an important
antimicrobial function in body fluids. Lactoferrin levels in
GCF and in whole saliva increased during EG [25, 26]. It
is possible that the local concentration of iron-binding
chelators in the oral cavity is important to prevent the
overgrowth of iron-requiring periodontal pathogens such
as P. gingivalis. If so, the concentration of these proteins
or the total iron sequestration capacity of saliva or GCF
may correlate with resistance against the induction of gin-
givitis. However, it is important to note that these studies
did not measure the total iron availability in saliva or GCF
and it is possible that the leakage of haem iron via GCF
from blood into these fluids may have led to increased
metal ions despite the elevated levels of chelators. Calpro-
tectin is another metal ion chelator, however its oral and
salivary levels were not so clear as lactoferrin. One study
found that calprotectin levels spiked briefly at the end of
the induction phase or immediately following professional
cleaning [12, 21]. It could be speculated that there are sen-
sors in the oral cavity to change salivary output of import-
ant antibacterial peptides during EG.
Several other biochemical markers with potential for re-
sistance and resilience to gingivitis have been identified,
and some of these have been noted in more than one
study. Unfortunately, none of the studies looking at bio-
chemical markers reported the details of individual re-
sponses to the EG protocol or of the rate of recovery of
markers during the resolution phase. Therefore, there is
still extensive work needed to identify potential biochem-
ical markers of responsiveness and resilience against EG.
Thus, the heterogeneity within the methods of the in-
cluded studies have made it difficult to compare results
or to draw firm conclusions based on consistent find-
ings. The limitations to compare the studies between
themselves were mainly in the differences in sample site,
duration of the trial, set-up of the trial (before, during
and after). For example, not all studies included a pre-
trial phase involving professional prophylaxis to reach a
non-inflammation status prior to the induction phase.
This might have influenced the results and differences
between the results when compared. Also, none of the
studies conducted power calculations, most likely result-
ing in underpowered results. Thus, the high level of no
significant changes found in many studies that did have
a resolution phase could have been due to the low
power. Furthermore, none of the studies used the terms
resistance or resilience, or specifically looked for oral re-
sistance and resilience. Resilience is a relatively new ap-
proach to oral health. Therefore, the interpretation of
resistance and resilience are drawn by the current au-
thors based on the findings and assumptions.
In light of the increasing evidence of different popula-
tion groups responding differentially to EG, the results of
the current systematic review have to be treated with cau-
tion until additional evidence provides a clear picture on
which of the discussed outcomes are characteristic for
specific populations. The majority of EG studies recruited
healthy young adults; it is highly questionable whether the
results on those subjects can be generalized to other age
groups, differences in resistance and resilience to EG can
be expected in older and younger participants. Indeed, in
one study the TNF-α levels in GCF indicated lower resist-
ance to EG in older participants, while in another study
on the same biomarker, young adults showed a resilience
in the resolution phase [17, 28]. Another difference be-
tween study groups was smoking. A well characterised dif-
ference is the bleeding response in an EG trial in smokers
vs. non-smokers [23, 26]. We extracted from studies that
smokers have a lower level of both cystatin C activity and
cystatin C salivary output than non-smokers, without cor-
responding differences for the other parameters such as
plaque index, parotid flow, salivary flow rate and total sal-
ivary protein [40].
In general we have noted from the current scoping re-
view, that the great majority of EG studies employed a
low to very low number of participants and essentially
all were underpowered. It is of high importance to draw
robust conclusions on the resistance and resilience of
the oral cavity eco-system and the gingival tissues, that
future EG studies follow the original EG-model includ-
ing a resolution phase, applying power calculations to
determine the appropriate population size. Also, for fu-
ture studies, smoking status should be biochemically
assessed to exclude misclassifications.
From our scoping review it is clear that currently we
miss the real insight on resistance and resilience of gin-
gival tissues and many other components of the oral cavity
to the EG challenge. The results which we extracted are in
fact ‘snapshots’ of non-fully comparable situations of EG.
These have led to our biggest challenge to draft a theory
on resistance and resilience to EG. In other words, the
studies included do not allow us to determine a clear pic-
ture on the oral ecological resistance and resilience, as cer-
tain biomarkers show different results in most studies
being also often of dissimilar design.
Conclusions
This study has highlighted a number of potential micro-
biological, immunological and biochemical markers that
may be useful for characterising the extent of resistance
Zemouri et al. BMC Oral Health          (2019) 19:212 Page 16 of 18
or resilience to the EG challenge. Further studies are
now required to determine the levels of individual vari-
ation in these parameters over the course of EG and
through resolution following the restoration of oral hy-
giene. Ultimately, it is important to understand individ-
ual response to plaque accumulation in order to better
manage dental care and how we can interfere to create
resistant and resilient oral ecosystems.
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